|Awarded On||August 19, 2020|
|Title||School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Starr, Zapata, and Jim Hogg County|
|Award Mechanism||Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Ana Rodriguez|
|Cancer Sites||Cervix Uteri|
*Pending contract negotiation
Need: The human papillomavirus (HPV) vaccine serves as an effective primary prevention strategy  by reducing morbidity and mortality of HPV-associated diseases (cervical, oropharyngeal, vulvar, vaginal, penile, anal cancer, anogenital warts) [2-10]. The overall annual direct medical cost of routine screening and treatment of HPV-associated disease is $8 billion (2010 USD). Direct costs could decrease if vaccination increased . It is recommended for girls and boys aged 11-12, with catch-up doses for those aged 13-26 [8, 10]. US completion rates (49.5% for girls and 49.3% for boys aged 13-17 years)  are not reaching Healthy People 2020 goal of 80% of 13-15-year-olds fully vaccinated...